biostudies-literatureUnknown376Harding C<h4>Objective</h4>To test and compare the efficacy of methenamine hippurate for prevention of recurrent urinary tract infections with the current standard prophylaxis of daily low dose antibiotics.<h4>Design</h4>Multicentre, open label, randomised, non-inferiority trial.<h4>Setting</h4>Eight centres in the UK, recruiting from June 2016 to June 2018.<h4>Participants</h4>Women aged ≥18 years with recurrent urinary tract infections, requiring prophylactic treatment.<h4>Interventions</h4>Random assignment (1:1, using permuted blocks of variable length via a web based system) to receive antibiotic prophylaxis or methenamine hippurate for 12 months. Treatment allocation was not masked and crossover between arms was allowed.<h4>Main outcome measure</h4>Absolute difference in incidence of symptomaBMJ (Clinical research ed.)e068229https://www.ebi.ac.uk/biostudies/studies/S-EPMC8905684biostudies-literatureAlternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial.PMC8905684Carnell SThiruchelvam NAbouhajar AHussain ZEardley IHarding CPickard RLecouturier JWatson GCurrer SKing WWalton KGuerrero KLazarowicz HAli AVale LForbes RChadwick THomer TMossop HPearce IfalseAlternative to prophylactic antibiotics for the treatment of recurrent urinary tract infections in women: multicentre, open label, randomised, non-inferiority trial.<h4>Objective</h4>To test and compare the efficacy of methenamine hippurate for prevention of recurrent urinary tract infections with the current standard prophylaxis of daily low dose antibiotics.<h4>Design</h4>Multicentre, open label, randomised, non-inferiority trial.<h4>Setting</h4>Eight centres in the UK, recruiting from June 2016 to June 2018.<h4>Participants</h4>Women aged ≥18 years with recurrent urinary tract infections, requiring prophylactic treatment.<h4>Interventions</h4>Random assignment (1:1, using permuted blocks of variable length via a web based system) to receive antibiotic prophylaxis or methenamine hippurate for 12 months. Treatment allocation was not masked and crossover between arms was allowed.<h4>Main outcome measure</h4>Absolute difference in incidence of symptoma2022-01-01T00:00:00Z2022 Mar2025-04-21T23:10:27.186Z2025-04-05T19:06:32.915ZS-EPMC89056843526440810.1136/bmj-2021-0068229